Finally, we discussed the bidirectional crosstalk between immunotherapy and the TME, particularly how immune checkpoint blockade (e.g., PD-1/PD-L1 inhibition) disrupts tumor immune evasion while causing unintended side effects on skeletal muscle homeostasis. Here, PDCD1 is linked to neoplasm.